Infliximab in psoriasis and psoriatic arthritis

BioDrugs

Volumn 27, Issue SUPPL. 1, 2013, Pages 13-23

  Papoutsaki, Marina ^a   Osório, Filipa ^b   Morais, Paulo ^b,c   Torres, Tiago ^d   Magina, Sofia ^b,c   Chimenti, Sergio ^e   Costanzo, Antonio ^e  

^a ANDREAS SYGROS HOSPITAL   (Greece)

^b Centro Hospitalar Universitário de São João   (Portugal)

^c University of Porto   (Portugal)

^d HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; INFLIXIMAB; METHOTREXATE;

ADULT; ARTHROPATHY; ARTICLE; CASE REPORT; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; ECHOGRAPHY; ENTHESITIS; FEMALE; HEADACHE; HUMAN; INFUSION RELATED REACTION; INTERPHALANGEAL JOINT; MAINTENANCE THERAPY; MALE; MIDDLE AGED; NAIL DISEASE; NAIL PSORIASIS; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; SCREENING; SKIN DISEASE; SYNOVITIS; SYSTEMIC THERAPY; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; CLINICAL TRIALS AS TOPIC; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NAILS; PSORIASIS; QUALITY OF LIFE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84892689986     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/BF03325638     Document Type: Article

References (41)

1. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58 (5): 826-50.
2. Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease. Br J Dermatol 1996; 135 (4): 533-7.
3. Augustin M, Kruger K, Radtke MA, et al. Disease severity, quality of life and health care in plaque-type psoriasis: A multicenter cross-sectional study in Germany. Dermatology 2008; 216 (4): 366-72.
4. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64 Suppl 2: II14-17.
5. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008; 58 (5): 851-64.
6. Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007; 57 (1): 1-27.
7. Williamson L, Dalbeth N, Dockerty JL, et al. Extended report: nail disease in psoriatic arthritis-clinically important, potentially treatable and often overlooked. Rheumatology (Oxford) 2004; 43 (6): 790-4.
8. Lawry M. Biological therapy and nail psoriasis. Dermatol Ther 2007; 20 (1): 60-7.
9. Reich K, Ortonne JP, Kerkmann U, et al. Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: A retrospective analysis of the EXPRESS Trial. Dermatology 2010; 221 (2): 172-8.
10. Augustin M, Reich K, Blome C, et al. Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol 2010; 163 (3): 580-5.
11. Baran R. The burden of nail psoriasis: An introduction. Dermatology 2010; 221 Suppl 1:1-5.
12. Langley RG, Dauden E. Treatment and management of psoriasis with nail involvement: A focus on biologic therapy. Dermatology 2010; 221 Suppl 1: 29-42.
13. Papoutsaki M, Costanzo A. Diagnosis and treatment of psoriasis and psoriatic arthritis. BioDrugs 2012; Citation to be confirmed at publication.
14. Centocor Ortho Biotech Inc. Remicade(RM) (infliximab) for IV injection. [Online] 2009; Available from: http://www.remicade.com/remicade/assets/HCP-PPI. pdf.
15. Electronic Medicines Compendium. Remicade 100mg powder for concentrate for solution for infusion. Summary of Product Characteristics. Schering- Plough Ltd. [Online] 2010; Available from: http://www.medicines.org.uk/emc/document. aspx?documentId=3236.
16. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, doubleblind trial. Lancet 2005; 366 (9494): 1367-74.
17. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56 (1): 31 e1-15.
18. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebocontrolled trial. J Am Acad Dermatol 2004; 51 (4): 534-42.
19. Reich K, Nestle FO, Papp K, et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: A randomized controlled trial. Br J Dermatol 2006; 154 (6): 1161-8.
20. Feldman SR, Gottlieb AB, Bala M, et al. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderateto- severe psoriasis. Br J Dermatol 2008; 159 (3): 704-10.
21. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005; 52 (4): 1227-36.
22. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64 (8): 1150-7.
23. Antoni CE, Kavanaugh A, van der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: Findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008; 35 (5): 869-76.
24. Kavanaugh A, Krueger GG, Beutler A, et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007; 66 (4): 498-505.
25. Woolacott N, Bravo Vergel Y, Hawkins N, et al. Etanercept and infliximab for the treatment of psoriatic arthritis: A systematic review and economic evaluation. Health Technol Assess 2006; 10 (31): Iii-iv, xiii-xvi, 1-239.
26. Tan AL, Rhodes LA, Marzo-Ortega H, et al. What imaging has told us about psoriatic arthritis. Rheumatology in Practice 2008; 5 (4): 14-16.
27. De Filippis LG, Caliri A, Lo Gullo R, et al.Ultrasonography in the early diagnosis of psoriasis-associated enthesopathy. Int J Tissue React 2005; 27 (4): 159-62.
28. Rich P, Scher RK. Nail Psoriasis Severity Index: A useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003; 49 (2): 206-12.
29. Noiles K, Vender R. Nail psoriasis and biologics. J Cutan Med Surg 2009; 13 (1): 1-5.
30. Reich K. Approach to managing patients with nail psoriasis. J Eur Acad Dermatol Venereol 2009; 23 Suppl 1: 15-21.
31. Bianchi L, Bergamin A, de Felice C, et al. Remission and timeof resolution of nail psoriasis during infliximab therapy. J Am Acad Dermatol 2005; 52 (4): 736-7.
32. Ash Z, Gaujoux-Viala C, Gossec L, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and metaanalysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2011; DOI: 10.1136/ard.2011.150995.
33. Adisen E, Aral A, Aybay C, et al. Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot study. J Dermatol 2010; 37 (8): 708-13.
34. Roux CH, Brocq O, Breuil V, et al. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford) 2007; 46 (4): 695-8.
35. Puig L, Barco D, Alomar A. Treatment of psoriasis with anti-TNF drugs during pregnancy: case report and review of the literature. Dermatology 2010; 220 (1): 71-6.
36. Cohen AD, Sherf M, Vidavsky L, et al. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008; 216 (2): 152-5.
37. Saraceno R, Schipani C, Mazzotta A, et al. Effect of anti-tumor necrosis factoralpha therapies on body mass index in patients with psoriasis. Pharmacol Res 2008; 57 (4): 290-5.
38. Briot K, Gossec L, Kolta S, et al. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment. J Rheumatol 2008; 35 (5): 855-61.
39. McGonagle D, Tan AL, Benjamin M. The nail as a musculoskeletal appendage- implications for an improved understanding of the link between psoriasis and arthritis. Dermatology 2009; 218 (2): 97-102.
40. Tan AL, Benjamin M, Toumi H, et al. The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis-a high-resolution MRI and histological study. Rheumatology (Oxford) 2007; 46 (2): 253-6.
41. Wortsman X, Jemec GB. Ultrasound imaging of nails. Dermatol Clin 2006; 24 (3): 323-8.